Phase 2 N=51 Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 Psychosis: Early Detection, Intervention and Prevention
Prodromal Schizophrenia · Psychotic Disorders · Severe Bipolar Disorder With Psychotic Features
Primary: Onset of Psychosis — 10; 14 percentage of sample converting
Phase 2 N=44 D-serine for the Schizophrenia Prodrome
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms (SOPS) Negative Scale — 7.6; 11.3 SOPS negative final score — p=0.03
N/A N=292 Early Detection and Intervention for the Prevention of Psychosis
Schizophrenia · Bipolar Disorder · Depression
Primary: Psychotic Symptoms — 9.2; 6.7 units on a scale — p=.0034
N/A N=165 Biomarkers in First Episode Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder, Depressed Type
Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL
Phase 3 N=8 Glycine vs Placebo for the Schizophrenia Prodrome
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms Total Score — 37.8; 37.5 units on a scale
Phase 2 N=63 N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Schizophrenic Psychoses
Primary: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS — 16.9; 17.2 units on a scale — p=0.50
N/A N=25 Feasibility of an Early Detection Program for Early Psychosis on a College Campus
Psychosis · First Episode Psychosis · Clinical High Risk for Psychosis
Primary: Duration of Untreated Psychosis
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
N/A N=77 Psychosis Screening in Juvenile Justice
Psychotic Disorders · Psychosis Nos/Other
Primary: Number of Participants Who Used Outpatient Mental Health Services — 20; 9 Participants — p=.053
N/A N=50 Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis
Attenuated Psychosis Syndrome
Primary: Brain Volume — 19.8; 54.8; -0.489; -6.28 Change in mm cubed (baseline -followup)
N/A N=8 Clinical Interviews With Detainees With Early Psychosis
First-Episode Psychosis
Primary: Number of Referrals to Correctional Health Services (CHS) — 8 Participants
Phase 1 N=127 NAPLS Omega-3 Fatty Acid Versus Placebo Study
Psychosis
Primary: Rate of Conversion to Psychosis. — 4; 3 Participants — p=.51
N/A N=191 Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis
Schizophrenia · First Episode Psychosis
Primary: Reducing the Duration of Untreated Psychosis — 5.32; 5.38 Days
N/A N=60 mHealth for Psychosis Help-seeking
Psychosis
Primary: Change in Treatment Seeking Steps — 6.43; 10.08; 7.65; 9.58 score on a scale
N/A N=60 Cognitive Markers in Prodromal MS
Multiple Sclerosis
Primary: Cerebral Metabolic Rate of Oxygen (CMRO2) — 8.17 micro-mol/100g/min
N/A N=14 First Episode Schizophrenia and Cannabis-Related Disorder Study
Cannabis-Related Disorder · Substance-Related Disorders · Schizophrenia
Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants
N/A N=120 Specialized Treatment Early in Psychosis (STEP)
Schizophrenia and Disorders With Psychotic Features
Primary: Number of Patients Hospitalized — 25; 14 participants — p=0.018
Phase 1 N=25 Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
Psychosis
Primary: Change From Baseline in Perceived Treatment Efficacy — 2.6; 1.6; 0.5; 0.5 score on a scale
N/A N=103 USS Training to Improve Social Function in People With Psychosis
Psychosis
Primary: Social Functioning Scale (SFS) Change — 1.28; 0.19; 1.56; 0.32 score on a scale
N/A N=24 rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia
Schizophrenia
Primary: Change in Precuneus Functional Activation — 0.0329; 0.067; -0.010 Beta coefficient change (Target vs Foil) — p=0.32
Phase 4 N=26 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01
N/A N=20 rTMS in First Episode Psychosis
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder
Primary: Cognitive Performance — 2.22; -0.50; 6.11; -3.70 BACS Composite Score
Phase 4 N=60 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
Phase 4 N=628 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not…
Phase 2 N=30 Diabetes in Neuropsychiatric Disorders
Schizophrenia
Primary: Body Mass Index — 22.1; 23.5; 24.2; 24.3 kg/m^2 — p=<0.001
N/A N=14 Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
Schizophrenia
Primary: Change in BOLD Signal in Anterior Cingulate Cortex — -0.0188; 0.0124 BOLD signal change (Mismatch vs. Match)
Phase 3 N=49 Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score — -10.2 Units on a scale — p=<0.0001
Phase 2 N=18 Cannabidiol Treatment in Patients With Early Psychosis
Schizophrenia · Schizoaffective Disorder
Primary: Positive and Negative Syndrome Scale (PANSS) Over Time — 81.3; 84.0; 78.3; 75.3 score on a scale — p=0.08
Phase 1 N=10 Weight Management Program for Patients With First Episode Psychosis
Diet, Healthy · Psychotic Disorders
Primary: Weight — -6; -3; -5; -4 Lbs